Ongoing Phase 3 waveLINE-010 Study of Zilovertamab Vedotin (ZV) Plus R-CHP Versus R-CHOP in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Authors

Russell Gollard
Jessica Flynn
Nishitha Reddy
Rushdia Yusuf
Anas Al-Janadi, Corewell Health West

Document Type

Conference Proceeding

Publication Date

9-2025

Publication Title

Clinical Lymphoma Myeloma & Leukemia

Volume

25

Issue

Suppl 1

First Page

s753

Comments

Society of Hematologic Oncology Annual Meeting, Sept 3-6, 2025, Houston, TX  

Last Page

s753

Recommended Citation

Gollard R, Flynn J, Reddy N, Yusuf R, Al-Janadi A. Ongoing Phase 3 waveLINE-010 Study of Zilovertamab Vedotin (ZV) Plus R-CHP Versus R-CHOP in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma Myeloma & Leukemia. 2025;25(Suppl 1):S753. doi: 10.1016/S2152-2650(25)02291-8.

DOI

10.1016/S2152-2650(25)02291-8

ISSN

2152-2650